Gain Therapeutics Inc

+0.11 (+3.41%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)42.42M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.33 Million
Adjusted EPS-$0.45
See more estimates
10-Day MA$3.45
50-Day MA$3.72
200-Day MA$4.17
See more pivots

Gain Therapeutics Inc Stock, NASDAQ:GANX

4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814
United States of America
Phone: +1.301.500.1556
Number of Employees: 32


Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.